Loading
Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.
Claire Harrison was principal investigator of COMFORT-II, the European trial showing the JAK inhibitor ruxolitinib shrinks spleens and improves symptoms compared with best available therapy in myelofibrosis, which with COMFORT-I made ruxolitinib the first approved MPN therapy. She has led the MAJIC, PT-1 and RESPONSE trials in polycythaemia vera and essential thrombocythaemia and chairs the UK MPN research network.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
Shares COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag mpn.
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre and the tag uk.
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.